Sorrento Therapeutics Files for Chapter 11 Bankruptcy | Goodman & Nekvasil P.A., May Recover Investor Losses
Sorrento Therapeutics Files for Chapter 11 Bankruptcy
Sorrento Therapeutics Inc. Bankruptcy Investigation
Sorrento Therapeutics Inc., filed for bankruptcy on February 13, 2023, after reportedly being hit with judgments totaling more than $173 million, according to the Wall Street Journal.
The problem with pharmaceutical and biotech investments is that they typically involve a high degree of risk. The research and development process for pharmaceutical companies often involves costly testing trials. If the expected data or end points are not met, that could yield bad results for investors.
As of its chapter 11 filing, Sorrento had over approximately $1 billion in assets.
Goodman & Nekvasil P.A. May Recover Investor Losses
If you lost money on investments in Sorrento Therapeutics you may be able to recover your losses.
Investments purchased in Sorrento Therapeutics may have been unsuitable or otherwise improper for you.
We would like to discuss the possibility of your retaining our firm to represent you in an arbitration action concerning improper sales practices by broker dealers who promoted Sorrento Therapeutics.
There is no charge for an evaluation of your case. We handle our cases on a contingency fee basis. If we don’t recover money for you, we charge no attorney’s fee.
Goodman & Nekvasil, P.A. has recovered more than $300 million on behalf of victimized investors. If you lost money on Sorrento Therapeutics and would like your case evaluated by a securities attorney, please contact us.
Some of the information in this blog post was obtained on 3/7/23 directly from FINRA BrokerCheck, without any changes. If you believe this information was reported incorrectly, please contact our firm at 1-800-500-4442.